1. Data on file. 2. Carpenedo M, Cantoni S, Mazzucconi MG, et al. Sequential use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Poster presented at: The 22nd European Hematology Association Congress; June 24, 2017; Madrid, Spain. Abstract P722. 3. Lakhwani S, Perera M, Fernández-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372-377. 4. Khellaf M, Viallard J-F, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881-887.
The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local Novartis representative for local prescribing information via https://www.novartis.com/our-company/contact-us.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)
US HCPs & Other
At right is a list of the countries that host a REVOLADE website based on local label and in a local language. They are intended for health care professionals (HCPs) only. If you are an HCP from one of the countries listed at right, click on your country’s link to be redirected to your country’s REVOLADE website.